CCDC88A

Across TCGA pan-cancer cohorts, CCDC88A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC88A data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CCDC88A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC88A expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where CCDC88A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	24	view →
PDAC	OS	Median	III,IV	0.615	0.897	.004	20	view →
LUAD	OS	Median	II,III,IV	0.862	1.000	.004	16	view →
GBM	DFS	Tertile	All	0.510	0.774	.028	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCDC88A–CCRCC (DFS)

Open the CCRCC breakdown →